The role and medical prospects of long non-coding RNAs in cardiovascular disease.
Najung KimWoo-Young ChungJe-Yeol ChoPublished in: Heart failure reviews (2023)
Cardiovascular disease (CVD) has reached epidemic proportions and is a leading cause of death worldwide. One of the long-standing goals of scientists is to repair heart tissue damaged by various forms of CVD such as cardiac hypertrophy, dilated cardiomyopathy, myocardial infarction, heart fibrosis, and genetic and developmental heart defects such as heart valve deformities. Damaged or defective heart tissue has limited regenerative capacity and results in a loss of functioning myocardium. Advances in transcriptomic profiling technology have revealed that long noncoding RNA (lncRNA) is transcribed from what was once considered "junk DNA." It has since been discovered that lncRNAs play a critical role in the pathogenesis of various CVDs and in myocardial regeneration. This review will explore how lncRNAs impact various forms of CVD as well as those involved in cardiomyocyte regeneration. Further, we discuss the potential of lncRNAs as a therapeutic modality for treating CVD.
Keyphrases
- cardiovascular disease
- heart failure
- long noncoding rna
- long non coding rna
- stem cells
- atrial fibrillation
- left ventricular
- single cell
- type diabetes
- network analysis
- poor prognosis
- aortic valve
- mesenchymal stem cells
- mitral valve
- climate change
- metabolic syndrome
- single molecule
- cardiovascular risk factors
- transcription factor
- public health
- rna seq
- cardiovascular events
- angiotensin ii
- cell free
- risk assessment
- genome wide identification